China-based Nanjing Healthnice Pharmaceutical Technology Co., Ltd has reportedly raised RMB100 million (USD14.8 million) in another financing round. The round was led by CICC ChuanHua Industrial Equity Investment Fund, with other investors including Sunland Fund and Jiangxi State-owned Industry Development Fund. The proceeds will be used for product pipeline layout and research and development (R & D) team expansion.
Company Background
Founded in 2001, Healthnice Pharma has developed an integrated business model combining contract research organization (CRO) and Marketing Authorization Holder (MAH) services, including manufacturing and sales. The company owns over 20 marketing approvals and has more than 60 programs under review or development.
Technology Platforms
Healthnice Pharma boasts core technology platforms such as a technology platform for directional synthesis and splitting of chiral drugs, a high-end preparation technology platform combining imitation and innovation, and a quality research technology platform. It has established workshops for various dosage forms, including oral solid preparations, oral liquid preparations, injections, pellets, gels, and ointments, totaling 10 dosage forms.-Fineline Info & Tech
